CoChat

CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies

Open access
Arévalo‐Martín, Á, García‐Ovejero, D, Gómez, O, Rubio‐Araiz, A, Navarro‐Galve, B, Guaza, C, Molina‐Holgado, E, Molina‐Holgado, F · 2008 · British Journal of Pharmacology
Cited by 73

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Amongst the various demyelinating diseases that affect the central nervous system, those induced by an inflammatory response stand out because of their epidemiological relevance. The best known inflammatory‐induced demyelinating disease is multiple sclerosis, but the immune response is a common pathogenic mechanism in many other less common pathologies (e.g., acute disseminated encephalomyelitis and acute necrotizing haemorrhagic encephalomyelitis). In all such cases, modulation of the immune response seems to be a logical therapeutic approach. Cannabinoids are well known immunomodulatory molecules that act through CB 1 and CB 2 receptors. While activation of CB 1 receptors has a psychotropic effect, activation of CB 2 receptors alone does not. Therefore, to bypass the ethical problems that could result from the treatment of inflammation with psychotropic molecules, considerable effort is being made to study the potential therapeutic value of activating CB 2 receptors. In this review we examine the current knowledge and understanding of the utility of cannabinoids as therapeutic molecules for inflammatory‐mediated demyelinating pathologies. Moreover, we discuss how CB 2 receptor activation is related to the modulation of immunopathogenic states. British Journal of Pharmacology (2008) 153, 216–225; doi:10.1038/sj.bjp.0707466; published online 24 September 2007

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0707466

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

Metadata

Authors
Arévalo‐Martín, Á., García‐Ovejero, D., Gómez, O., Rubio‐Araiz, A., Navarro‐Galve, B., Guaza, C., Molina‐Holgado, E., & Molina‐Holgado, F.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2008-01
Volume
153
Issue
2
Pages
216-225
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2077322233
Cited by
73
References
15
FWCI
4.51
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.